DURECT Corporation - Drug delivery technologies treating chronic debilitating disease

Board of Directors

Corporate Policies/Governance

Driving Directions

Development Pipeline

Commercial Products

Research Programs

Business Development Approach

The SABER™ Delivery System

ORADUR® Gel-Cap System

TRANSDUR® Transdermal Technology System

DURIN™ System

MICRODUR™ System

Localized Drug Delivery

Stock Information

Corporate Presentation

Earnings Estimate

Analyst Coverage

Financial Reports

Information Request

Benefits Overview

Attention Recruiters

About DURECT

Products

Business Development

Science & Technologies

Investor Relations

Careers

News

DURECT: Developing products to treat chronic debilitating disease and technologies that enable biotechnology products.

DURECT Featured Clinical Products

Latest News

POSIDUR

Indication:

Focus:

Post-Surgical Pain

POSIDUR™
A sustained-release formulation of a local anesthetic using our SABER™ Delivery System for the treatment of post surgical pain.

Learn more
View complete product pipeline

January 30, 2012
DURECT Receives Back European Product Rights to POSIDUR™

January 05, 2012
DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)

January 05, 2012
Durect Corp to Discuss POSIDUR Clinical Trial Results

November 07, 2011
DURECT Corporation to Participate in Upcoming Healthcare Conferences

November 03, 2011
DURECT Corporation Announces Third Quarter 2011 Financial Results and Update of Programs

2010 Annual Report

2010 Annual Report

© 2000-2012 DURECT Corporation

Last updated: April 12, 2011
built@zoomedia.com

Contact